E
Gain Therapeutics, Inc.
GANX
$1.58
-$0.07-4.24%
E
Sell
9/6/2024Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 9/6/2024 due to a decline in the volatility index and total return index.
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 9/6/2024 due to a decline in the volatility index and total return index.
D
Sell
8/22/2024Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 8/22/2024 due to an increase in the valuation index and solvency index. Debt to equity declined from 0.08 to 0.06, and the quick ratio increased from 2.58 to 2.64.
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 8/22/2024 due to an increase in the valuation index and solvency index. Debt to equity declined from 0.08 to 0.06, and the quick ratio increased from 2.58 to 2.64.
E
Sell
11/17/2023Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 11/17/2023 due to a decline in the valuation index, volatility index and solvency index. Debt to equity increased from 0.07 to 0.11, and the quick ratio declined from 2.93 to 2.14.
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 11/17/2023 due to a decline in the valuation index, volatility index and solvency index. Debt to equity increased from 0.07 to 0.11, and the quick ratio declined from 2.93 to 2.14.
D
Sell
10/26/2023Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 10/26/2023 due to an increase in the valuation index.
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 10/26/2023 due to an increase in the valuation index.
E
Sell
8/14/2023Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 8/14/2023 due to a decline in the growth index, total return index and volatility index. EBIT declined 47.83% from -$5.23M to -$7.73M, earnings per share declined from -$0.4304 to -$0.6206, and operating cash flow declined 19.06% from -$4.22M to -$5.02M.
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 8/14/2023 due to a decline in the growth index, total return index and volatility index. EBIT declined 47.83% from -$5.23M to -$7.73M, earnings per share declined from -$0.4304 to -$0.6206, and operating cash flow declined 19.06% from -$4.22M to -$5.02M.
D
Sell
6/6/2023Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index, valuation index and total return index.
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index, valuation index and total return index.
E
Sell
5/22/2023Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 5/22/2023 due to a noticeable decline in the growth index, solvency index and valuation index. The quick ratio declined from 4.93 to 3.49, debt to equity increased from 0.04 to 0.05, and EBIT declined 14.66% from -$4.56M to -$5.23M.
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 5/22/2023 due to a noticeable decline in the growth index, solvency index and valuation index. The quick ratio declined from 4.93 to 3.49, debt to equity increased from 0.04 to 0.05, and EBIT declined 14.66% from -$4.56M to -$5.23M.
D
Sell
3/2/2023Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 3/2/2023 due to a decline in the volatility index and valuation index.
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 3/2/2023 due to a decline in the volatility index and valuation index.
D
Sell
2/15/2023Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D from E+ on 2/15/2023 due to an increase in the total return index.
Gain Therapeutics, Inc. (GANX) was upgraded to D from E+ on 2/15/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.04, and the quick ratio declined from 7.18 to 5.29.
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.04, and the quick ratio declined from 7.18 to 5.29.
D
Sell
9/23/2022Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 9/23/2022 due to a decline in the volatility index.
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 9/23/2022 due to a decline in the volatility index.
D
Sell
9/7/2022Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D from D- on 9/7/2022 due to an increase in the total return index, volatility index and valuation index.
Gain Therapeutics, Inc. (GANX) was upgraded to D from D- on 9/7/2022 due to an increase in the total return index, volatility index and valuation index.
D
Sell
8/1/2022Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 8/1/2022 due to a decline in the volatility index and valuation index.
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 8/1/2022 due to a decline in the volatility index and valuation index.
D
Sell
6/28/2022Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D from D- on 6/28/2022 due to an increase in the volatility index and total return index.
Gain Therapeutics, Inc. (GANX) was upgraded to D from D- on 6/28/2022 due to an increase in the volatility index and total return index.
D
Sell
6/13/2022Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
Gain Therapeutics, Inc. (GANX) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
D
Sell
5/20/2022Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D from D- on 5/20/2022 due to an increase in the growth index. Operating cash flow increased 40.98% from -$4.15M to -$2.45M, and total revenue increased 3.31% from $36.3 to $37.5.
Gain Therapeutics, Inc. (GANX) was upgraded to D from D- on 5/20/2022 due to an increase in the growth index. Operating cash flow increased 40.98% from -$4.15M to -$2.45M, and total revenue increased 3.31% from $36.3 to $37.5.
D
Sell
5/5/2022Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
3/29/2022Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 3/29/2022 due to a large increase in the growth index. Total revenue increased 126.88% from $16 to $36.3, earnings per share increased from -$0.3927 to -$0.2706, and EBIT increased 30.78% from -$4.64M to -$3.21M.
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E+ on 3/29/2022 due to a large increase in the growth index. Total revenue increased 126.88% from $16 to $36.3, earnings per share increased from -$0.3927 to -$0.2706, and EBIT increased 30.78% from -$4.64M to -$3.21M.
E
Sell
3/15/2022Downgrade
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 3/15/2022 due to a decline in the volatility index and total return index.
Gain Therapeutics, Inc. (GANX) was downgraded to E+ from D- on 3/15/2022 due to a decline in the volatility index and total return index.
D
Sell
12/1/2021Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E on 12/1/2021 due to a large increase in the solvency index and valuation index.
Gain Therapeutics, Inc. (GANX) was upgraded to D- from E on 12/1/2021 due to a large increase in the solvency index and valuation index.
E
Sell
9/1/2021Upgraded
Gain Therapeutics, Inc. (GANX) was upgraded to E from E- on 9/1/2021 due to an increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.5033 to -$0.2995.
Gain Therapeutics, Inc. (GANX) was upgraded to E from E- on 9/1/2021 due to an increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.5033 to -$0.2995.
E
Sell
6/11/2021None
Gain Therapeutics, Inc. (GANX) was downgraded to E- from U on 06/11/2021.
Gain Therapeutics, Inc. (GANX) was downgraded to E- from U on 06/11/2021.
NASDAQ
04/10/2025 4:00PM Eastern
Quotes delayed
